Collaborations

Viruses - Open Access Virology Journal

Viruses (ISSN 1999-4915) is an open access journal that provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications and conference reports and short notes. Our aim is to publish papers that are of significant impact to the virology community, and to help researchers present their cutting-edge findings and opinions in detail and have quick dissemination among their peers. We encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced. There is no restriction on the length of the papers. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community.
GfV members will now receive a 20% discount on the article processing charges for publishing in Viruses, as well as other benefits.

Journal of General Virology

Journal of General Virology is led by a carefully selected, prestigious Editorial Board who ensure rigorous, high-quality peer review, aided by the Society’s in-house publishing team. Authors benefit from rapid publication times and very liberal Open Access policies, which comply with all funder and institutional Open Access mandates worldwide, and are not subject to page limits, page charges or colour fees.
Tasha Mellins-Cohen, Director of Publishing at the Microbiology Society, said “The Journal of General Virology is a fantastic journal with a long history of publishing virology research from around the world, and we are very excited to partner with the GfV to raise the profile of the Journal with our colleagues in Germany, Austria, Switzerland and other German-speaking areas.”
GfV members will now receive a 20% discount on the article processing charges for publishing in Journal of General Virology.

AiCubator – a new way of collaboration in the anti-infective aera

You are an academic group or a recently formed biotech start-up with antiviral or
antibacterial projects?
You have identified a new breakthrough mechanism of action with supporting data?
You want this invention to become a therapy for patients?
You are looking for support and guidance on your way?

Then we encourage you to apply for AiCubator resident status to get support and industry knowledge from one of the leaders in anti-infective drug development.
Drug discovery project in the following indications:
• Targeted antiviral therapy for:
– Hepatitis B virus (HBV cure)
– BK Virus
– Epstein-Barr virus
– Adenovirus
• Antibacterial (non-small molecule) therapy for:
– Bloodstream infections
– Diabetic foot infections
Novel platform approach
We welcome projects, that are scientifically attractive, but too early for licensing deals.
Keen to apply for AiCubator Resident status? Download the application form from the website
www.aicubator.eu
Describe your innovation and needs in the form.
Additional questions?
aicubator@aicuris.com
More information?
www.aicubator.eu
Send it to aicubator@aicuris.com until the end of
2021 and become one of the AiCubator residents
by 2022.
Work together with anti-infective drug
development experts
APPLY NOW!

Contact

Fragen, Feedback und Wünsche können Sie per Mail (geschaeftsstelle@g-f-v.org) oder mit dem Kontaktformular an uns adressieren.

3 + 2 =

Association for Applied Hygiene e.V.

The VAH promotes the application-oriented scientific processing and implementation of hygienic and hygiene-relevant topics. This includes the development of test specifications and evaluation options for decontamination, disinfection, antisepsis and sterilisation procedures, the exchange of experience and interdisciplinary cooperation with relevant medical and non-medical disciplines. Last but not least, the planning and implementation of further education and training and answering user questions is an important area of responsibility.

The work of the Disinfectants Commission in the VAH is committed to the goals of public health protection. The certification of disinfectants and the publication of the VAH list are intended to ensure that only hygienically-microbiologically or hygienically-virologically tested disinfection procedures with proven effectiveness are used. The effects on humans and the environment during use, e.g. by preventing overdoses, are also taken into account.

Members of the VAH include scientific societies and professional associations as well as experts from the fields of hygiene, public health and infectiology.